[A23-132] Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76
Last updated 01.02.2024
Project no.:
A23-132
Commission:
Commission awarded on 12.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adult patients with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM)
After addendum now: hint of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-132_en
| Project no. | Title | Status |
|---|---|---|
| A23-76 | Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-01 A G-BA decision was published.